These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34952558)

  • 1. Vaccination in Leishmaniasis: A Review Article.
    Abdellahi L; Iraji F; Mahmoudabadi A; Hejazi SH
    Iran Biomed J; 2022 Jan; 26(1):1-35. PubMed ID: 34952558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P; Tacchini-Cottier F; Kieny MP
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
    Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
    Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines and vaccination strategies against human cutaneous leishmaniasis.
    Okwor I; Uzonna J
    Hum Vaccin; 2009 May; 5(5):291-301. PubMed ID: 19221514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of live attenuated vaccines against Cutaneous Leishmaniasis.
    Zabala-Peñafiel A; Todd D; Daneshvar H; Burchmore R
    Exp Parasitol; 2020 Mar; 210():107849. PubMed ID: 32027892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
    Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against cutaneous leishmaniasis: current status.
    Melby PC
    Am J Clin Dermatol; 2002; 3(8):557-70. PubMed ID: 12358557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
    Dinc R
    Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
    Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immunity and Leishmania vaccination strategies.
    Birnbaum R; Craft N
    Dermatol Clin; 2011 Jan; 29(1):89-102. PubMed ID: 21095533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
    Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
    Seyed N; Peters NC; Rafati S
    Front Immunol; 2018; 9():1227. PubMed ID: 29922288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Leishmanization Using
    Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
    Front Immunol; 2020; 11():1725. PubMed ID: 33193290
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioinformatics analyses of immunogenic T-cell epitopes of LeIF and PpSP15 proteins from Leishmania major and sand fly saliva used as model antigens for the design of a multi-epitope vaccine to control leishmaniasis.
    Bordbar A; Bagheri KP; Ebrahimi S; Parvizi P
    Infect Genet Evol; 2020 Jun; 80():104189. PubMed ID: 31931259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
    Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
    J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.